Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | FBP1 | P09467 | 12/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13188853 | 0.81 | KMT2A (0.81) | KMT2AALDH1A1FBP1AKR1C3KAT6A | |
| SCHEMBL17277340 | 0.81 | KMT2A (0.81) | KMT2AALDH1A1FBP1AKR1C3KAT6A | |
| SCHEMBL4617581 | 0.81 | ATM (0.55) | KMT2AALDH1A1AKR1C3ATM | |
| SCHEMBL3687106 | 0.81 | ALDH1A1 (0.61) | ALDH1A1ATM | |
| SCHEMBL11707958 | 0.80 | KMT2A (0.83) | KMT2AALDH1A1FBP1AKR1C3KAT6A | |
| SCHEMBL5183959 | 0.79 | CA1 (0.58) | KMT2AALDH1A1ATM | |
| SCHEMBL11815256 | 0.79 | KMT2A (0.76) | KMT2AALDH1A1FBP1AKR1C3KAT6A | |
| SCHEMBL24956750 | 0.78 | KMT2A (0.74) | KMT2AALDH1A1FBP1KAT6A | |
| SCHEMBL8548241 | 0.77 | KMT2A (0.78) | KMT2AALDH1A1FBP1AKR1C3KAT6A | |
| SCHEMBL19000452 | 0.77 | KMT2A (0.71) | KMT2AALDH1A1FBP1AKR1C3KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| EP-1334100-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333829-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040469-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040022-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | KMT2A 4282/4885ALDH1A1 3512/4885FBP1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.